Effects of Probiotics (BioKid LR - Contains Nine Different Species of Probiotics Bacteria Including L. Reuteri) in Children With Functional Constipation
Launched by FERASS ABU HANNA · May 5, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a probiotic supplement called BioKid LR® can help children with functional constipation after they stop using a common laxative, PEG 3350. The study is looking for children aged 6 months to 17 years who have been diagnosed with functional constipation. Participants will first take PEG 3350 for 12 weeks and then gradually stop while continuing to take either BioKid LR or a placebo (an inactive powder) for an additional 12 weeks. The aim is to see if taking BioKid LR helps prevent constipation from returning and allows children to have regular bowel movements without needing to restart laxatives.
In total, about 80 children will be involved in the study, and neither the families nor the doctors will know who is receiving the real probiotic or the placebo. Participants will keep a diary to track their bowel habits and attend five visits for check-ups. To be eligible, children must be between 6 months and 17 years old and have a diagnosis of functional constipation, but those with certain medical conditions, like celiac disease or thyroid issues, cannot take part. This study has been approved by an ethics committee and is being conducted following strict guidelines to ensure safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 0.5 - 17 years
- • 2. Diagnosis of FC based on Rome IV criteria
- Exclusion Criteria:
- • 1. Children with chronic diseases which could cause constipation: Celiac disease, food allergy, Hypothyroidism, Inflammatory Bowel Disease, electrolytes disturbances, Cystic fibrosis, Hirschsprung disease, Neuropathic conditions (Spinal cord trauma, Neurofibromatosis, Tethered cord) or intestinal pseudo-obstruction
- • 2. Prematurity (\<34 weeks)
- • 3. S/P intestinal surgery
- • 4. Immunodeficiency
- • 5. Malignancy
- • 6. Children treated with medications associated with constipation. \*
About Ferass Abu Hanna
Ferass Abu Hanna is a dedicated clinical trial sponsor renowned for advancing innovative research in the healthcare sector. With a focus on developing novel therapies and improving patient outcomes, the organization collaborates with leading research institutions and healthcare professionals to conduct rigorous clinical studies. Committed to ethical practices and regulatory compliance, Ferass Abu Hanna prioritizes patient safety and data integrity, striving to contribute meaningful advancements in medical science and foster breakthroughs in treatment options. Through its comprehensive approach, the sponsor plays a pivotal role in translating scientific discoveries into tangible healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Afula, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported